CSBio CSBio

X
[{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioArctic Receives Patent in Japan for New Antibodies Targeting Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"SWEDEN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"BioArctic AB"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The allowed patent application focuses on novel antibodies which target pE3-Aβ, a specific truncated form of amyloid beta and are linked to the company’s project AD1503.

            Lead Product(s): AD1503

            Therapeutic Area: Neurology Product Name: AD1503

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 11, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY